Want to see GB:EMVC full AI Analyst Report?
Top Page
NetScientific
(LSE:EMVC)
Select Model
Select Model
Rating:42Neutral
Price Target:
49.00 p
▼(-19.01% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily held back by weak financial quality—ongoing operating losses and persistent negative operating/free cash flow—despite improving revenue growth and a near-breakeven net result in 2025. Technicals also remain weak with the stock trading below key longer-term moving averages and a negative MACD, while valuation support is limited due to negative earnings and no dividend yield data.
Positive Factors
Niche life-sciences investment focus
A focused mandate on early-stage life-science assets gives durable strategic advantage: sector specialization improves deal sourcing, technical diligence, and post-investment support. Over months this enhances the probability of value-creating exits and compounding portfolio gains versus a generalist approach.
Negative Factors
Consistent negative operating cash flow
Persistent operating cash burn is a structural weakness: it forces reliance on external financing or balance-sheet drawdowns to sustain operations and investment activity. Over months this elevates dilution and refinancing risk and constrains the firm's ability to seize opportunistic follow-ons or exits.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche life-sciences investment focus
A focused mandate on early-stage life-science assets gives durable strategic advantage: sector specialization improves deal sourcing, technical diligence, and post-investment support. Over months this enhances the probability of value-creating exits and compounding portfolio gains versus a generalist approach.
Read all positive factors
NetScientific (EMVC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£14.40M
Dividend YieldN/A
Average Volume (3M)31.99K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth16.98%
EPS Growth99.21%
CountryUK
Employees29
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding27,967,531
10 Day Avg. Volume35,929
30 Day Avg. Volume31,987
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)1.04
Price to Sales (P/S)5.52
P/FCF Ratio-12.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)£3.43M
NetScientific Business Overview & Revenue Model
Company Description
EMV Capital plc operates as a venture capital firm, primarily targeting investments across the full spectrum of early-stage funding, from seed rounds through to mid-stage and growth capital. Its investment mandate spans diverse high-growth sectors...
How the Company Makes Money
NetScientific makes money primarily through investment returns generated by its portfolio. Key potential revenue/value sources include: (1) Realized gains on exits: profits from selling equity stakes in portfolio companies via trade sales, mergers...
NetScientific Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.87M | 2.45M | 1.45M | 1.00M | 1.11M |
| Gross Profit | 2.25M | 2.09M | 1.23M | 782.00K | 989.00K |
| EBITDA | -1.52M | -3.12M | -2.27M | -3.31M | -2.65M |
| Net Income | -21.00K | -3.06M | -2.64M | -3.09M | -2.38M |
Balance Sheet | |||||
| Total Assets | 19.78M | 19.50M | 22.46M | 28.95M | 20.69M |
| Cash, Cash Equivalents and Short-Term Investments | 511.00K | 949.00K | 347.00K | 580.00K | 2.35M |
| Total Debt | 2.60M | 1.53M | 2.53M | 1.25M | 654.00K |
| Total Liabilities | 6.13M | 5.43M | 5.35M | 3.71M | 2.18M |
| Stockholders Equity | 15.21M | 15.10M | 17.83M | 25.84M | 18.50M |
Cash Flow | |||||
| Free Cash Flow | -1.27M | -1.97M | -3.51M | -3.16M | -3.54M |
| Operating Cash Flow | -1.24M | -1.78M | -3.14M | -2.56M | -3.48M |
| Investing Cash Flow | 279.00K | 12.00K | 1.11M | -1.08M | -3.46M |
| Financing Cash Flow | 477.00K | 2.57M | 1.39M | 1.74M | 8.02M |
NetScientific Technical Analysis
Positive
60.50
Price Trends
47.94
Positive
51.40
Positive
51.38
Positive
Market Momentum
0.98
Negative
67.14
Neutral
51.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EMVC, the sentiment is Positive. The current price of 60.5 is above the 20-day moving average (MA) of 49.80, above the 50-day MA of 47.94, and above the 200-day MA of 51.38, indicating a bullish trend. The MACD of 0.98 indicates Negative momentum. The RSI at 67.14 is Neutral, neither overbought nor oversold. The STOCH value of 51.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EMVC.
NetScientific Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
62 Neutral | £17.10M | 4.71 | 16.48% | ― | 543.02% | 30.22% | |
43 Neutral | £11.97M | -1.28 | -14.62% | ― | 7.43% | -51.54% | |
42 Neutral | £14.40M | -515.00 | -16.69% | ― | 16.98% | 99.21% | |
42 Neutral | £18.39M | -2.59 | -36.43% | ― | 16.29% | 30.51% |
* Financial Sector Average
GB:EMVC
NetScientific
51.50
5.50
11.96%
GB:FIPP
Frontier IP
14.50
-6.50
-30.95%
GB:MAFL
Mineral & Financial Investments
44.00
20.50
87.23%
GB:TEAM
TEAM plc
16.00
-18.00
-52.94%
NetScientific Corporate Events
Business Operations and StrategyShareholder Meetings
EMV Capital Secures Shareholder Backing for All AGM Resolutions
Positive
Jun 17, 2026
EMV Capital plc said that all resolutions proposed at its 2026 annual general meeting were duly passed, including the adoption of its 2025 accounts, approval of the directors’ remuneration report and reappointment of BDO as auditor. Sharehol...
Financial DisclosuresShareholder Meetings
EMV Capital Publishes 2025 Annual Report and Sets June AGM
Neutral
May 22, 2026
EMV Capital plc has posted its Annual Report and Accounts for the year ended 31 December 2025, along with the notice of its upcoming annual general meeting, to shareholders, and has made the documents available on its investor website. The AGM is ...
Business Operations and StrategyProduct-Related Announcements
EMV Capital’s AMR Bio pushes XF-73 antimicrobial towards Phase 3 in major infection markets
Positive
May 21, 2026
EMV Capital has reported a commercial update on portfolio company AMR Bio, which is advancing its first-in-class topical antimicrobial XF-73 from successful Phase 2b trials towards Phase 3 development. AMR Bio has built an experienced management t...
Business Operations and StrategyFinancial Disclosures
EMV Capital narrows losses as assets under management climb and venture portfolio gains traction
Positive
May 19, 2026
EMV Capital reported a strong 2025 despite a challenging funding environment, growing assets under management to £112.5 million and expanding recurring and transactional revenues, aided by the full integration of the Martlet Capital practice....
Business Operations and StrategyExecutive/Board Changes
EMV Capital Launches Phantom Carry Scheme to Align Leadership with Investor Returns
Positive
May 19, 2026
EMV Capital has adopted a new phantom carried interest scheme to provide long-term, performance-linked incentives to its executive directors and senior leadership. The cash-based scheme ties rewards to investment returns from portfolio exits, inco...
Business Operations and StrategyFinancial Disclosures
EMV Capital Sets Date for 2025 Final Results and Investor Presentation
Positive
May 14, 2026
EMV Capital plc will publish its final results for the year ended 31 December 2025 on 19 May 2026, underscoring its ongoing communication with the market as an AIM-quoted deep tech and life sciences venture investor. The company will host an onlin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.